Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9393705 | 1.00 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL6559404 | 1.00 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL6559406 | 1.00 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL7915780 | 0.92 | UPP1 (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL7915783 | 0.92 | UPP1 (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL7516274 | 0.92 | PNP (0.52) | LMNATP53UPP1P2RY1PNP | |
| SCHEMBL10624665 | 0.92 | UPP1 (0.43) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL10624661 | 0.92 | UPP1 (0.43) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL13664950 | 0.91 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL15031043 | 0.91 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203862-A1 | Antisense modulation of MDM2 expression | ISIS PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203862-A1 | Antisense modulation of MDM2 expression | MDM2, TP53, DCLRE1B | LMNA 2063/4885TP53 2/4885ALDH1A1 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.